San Diego-dependent Viking Therapeutics marked itself as a significant competitor during the weight loss drug sector in February just after revealing promising knowledge from a mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs w